RTTNews | Oct 18, 2021 08:27AM EDT

08:27 Monday, October 18, 2021 (RTTNews.com) - Adamis Pharmaceuticals Corporation (ADMP) announced the FDA has approved ZIMHI 5 mg/0.5 mL, a high-dose naloxone injection for use in the treatment of opioid overdose. The company is preparing for the full commercial launch of ZIMHI in the first quarter of 2022.

Dennis Carlo, CEO of Adamis, said, "We are very excited by this approval and are working with our commercial partner, US WorldMeds, to make this much-needed, lifesaving product readily available to the market."

Shares of Adamis Pharmaceuticals Corporation were up 23% in pre-market trade on Monday.

Read the original article on RTTNews ( https://www.rttnews.com/3233280/adamis-pharma-reports-fda-approval-of-zimhi-in-treatment-of-opioid-overdose-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved